Prostate Cancer Prevention Trial Study Reanalyzed

Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.The study of the Prostate Cancer Prevention Trial, led by University of Illinois at Chicago professor of pathology Dr. Peter Gann, is published in the Journal of the National Cancer Institute. [click link for full article]

More: continued here

Filed under: Clinical Trials on September 20th, 2007